Dr. Gilda Ennis, PhD, Gleason Lab Scientist gave an oral presentation on research describing the performance of blood-based p-tau217, a biomarker of Alzheimer’s disease (AD), in Black Americans enrolled in the African Americans Fighting Alzheimer’s in Midlife study. These data were presented at the 2024 Clinical Trials on Alzheimer’s Disease (CTAD) conference held from October 29 – November 1 in Madrid, Spain.